Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution
Alembic Pharmaceuticals Ltd 路 Press Release 路 05 Nov 2026, 3:26 am
Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution Alembic Pharmaceuticals has secured USFDA final approval for its ANDA Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), therapeutically equivalent to Alcon鈥檚 Pataday Once Daily Relief. Developed with Orbicular Pharmaceutical Technologies, the product targets itchy eyes relief, addressing an estimated US market size of US$20 million for the 12 months ending Sep'26. This approval increases Alembic鈥檚 cumulative USFDA tally to 248 ANDA approvals, comprising 229 final approvals and 19 tentative approvals.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
